je.st
news
Tag: pharmaceuticals
Remedy Pharmaceuticals Announces Contest To Name Its Subarachnoid Hemorrhage Clinical Trial
2016-06-08 04:14:03| drugdiscoveryonline News Articles
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, recently announced a contest to name its upcoming clinical trial in Subarachnoid Hemorrhage (SAH)
Tags: trial
clinical
contest
announces
Syros Pharmaceuticals Announces FDA Acceptance Of IND To Advance SY-1425 Into Phase 2 Clinical Trial
2016-06-01 04:49:19| drugdiscoveryonline Home Page
Syros Pharmaceuticals recently announced that the U.S. Food and Drug Administration (FDA) accepted the Company’s Investigational New Drug (IND) application to advance its lead drug candidate, SY-1425, a potent and selective retinoic acid receptor alpha (RARα) agonist, into a Phase 2 clinical trial in genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia (AML) and relapsed high-risk myelodysplastic syndrome (MDS) identified through its platform
Tags: trial
advance
phase
acceptance
Recursion Pharmaceuticals Announces Research Agreement With Sanofi Genzyme
2016-05-03 03:24:14| drugdiscoveryonline News Articles
Recursion Pharmaceuticals recently announced a research agreement with Sanofi Genzyme, the specialty care global business unit of Sanofi, to deploy its drug repurposing platform to identify new uses for Sanofi’s clinical stage molecules across dozens of genetic diseases
Tags: research
agreement
announces
pharmaceuticals
Valeant Pharmaceuticals Intl Inc (VRX) Receives Underperform Rating from Wells Fargo
2016-04-15 22:46:50| Biotech - Topix.net
's stock had its "underperform" rating restated by research analysts at Wells Fargo in a report issued on Friday, MarketBeat.com reports. Shares of Valeant Pharmaceuticals Intl traded down 0.03% during midday trading on Friday, reaching $32.35.
Tags: rating
receives
wells
intl
Transplant Genomics And Quark Pharmaceuticals Announce Discovery And Development Collaboration
2016-04-15 03:46:09| drugdiscoveryonline Home Page
Transplant Genomics Inc. ("TGI") and Quark Pharmaceuticals, Inc. ("Quark") today announced their joint intent to pursue a discovery and development collaboration involving the use of TGI's TruGraf™ blood test in a Phase 3 clinical trial involving patients being treated for delayed graft function (DGF) with Quark's proprietary drug candidate QPI-1002.
Tags: development
collaboration
discovery
announce
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] next »